Related Experiment Video
Updated: May 5, 2026
10:17
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
22.8K
Candidate gene polymorphisms and power athlete status: a meta-analytical approach
Gökhan İpekoğlu1, Tuğba Çetin2, Tülay Sırtbaş1
1Faculty of Sport Science, Ordu University, Ordu, Turkey.
Journal of Physiology and Biochemistry
|March 7, 2025
Summary
Certain genetic variations, like GALNTL6 rs558129 and NOS3 rs2070744, are linked to power athlete status. These genetic polymorphisms may serve as important markers for identifying athletic potential.
Area of Science:
- Sports Science
- Genetics
- Human Physiology
Background:
- Athlete status is influenced by various factors, including genetics.
- Identifying genetic markers associated with athletic performance is an ongoing area of research.
Purpose of the Study:
- To conduct a meta-analysis investigating the association between athlete status and specific candidate genetic polymorphisms.
- To evaluate the prevalence of selected genetic variations in power athletes compared to control groups.
Main Methods:
- Meta-analysis of 23 case-control studies published between 2009 and 2022.
- Data sourced from PubMed and Web of Science databases.
- Analysis using random or fixed effects models with evaluation of odds ratios and confidence intervals.
Main Results:
- The GALNTL6 rs558129 T/T genotype, MCT1 rs1049434 T/T genotype, and NOS3 rs2070744 T allele/genotype were more prevalent in power athletes.
- Conversely, GALNTL6 rs558129 C allele/genotype and AGTR2 rs11091046 C allele/genotype were more common in the control group.
- Statistical significance (p < 0.05) was observed for these associations.
Conclusions:
- Specific genetic polymorphisms, including GALNTL6 rs558129, MCT1 rs1049434, and NOS3 rs2070744, show a significant association with power athlete status.
- These findings suggest that certain genetic markers could be valuable in identifying individuals with a predisposition for power-based athletics.
- Further research is warranted to validate and expand upon these genetic associations in athletic populations.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
14.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
01:27Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129